<\/span><\/h1>\n\n\n\nEvery route from cell reprogramming to a treatment, ordered by how close it actually is to a human being \u2014 and where a topical wound programme could enter.<\/p>\n\n\n\n
Prepared for E. Feoli-TufiPol\u00edmeros y Servicios S.A.Scope: chemical & pharmacological routes<\/p>\n\n\n\n
The governing constraint<\/p>\n\n\n\n
Chemical reprogramming is not self-sustaining.<\/strong> Cells require continuous compound exposure for weeks; withdraw early and they relax back. The only state that maintains itself after withdrawal is full pluripotency \u2014 the one state you can never induce inside a person, because it forms teratomas.<\/p>\n\n\n\nEverything below follows from that. The chemistry is a manufacturing process<\/em>, not a therapy. Which means the whole field splits into two routes that have almost nothing in common except vocabulary.<\/p>\n\n\n\nRoute A<\/p>\n\n\n\n
<\/span>Ex vivo \u2014 the factory<\/span><\/h2>\n\n\n\nReprogram cells outside the body under controlled chemistry, differentiate them, transplant the product. Nothing self-sustaining about the chemistry; what persists is the graft. Regulatory class: advanced cell therapy. Cost structure: per-patient manufacture, cleanroom, months of lead time.<\/p>\n\n\n\n
Bench \/ preclinicalIn trialsFiled with regulatorReached patientsDiscontinued<\/p>\n\n\n\n
<\/span>Autologous CiPSC-derived islets, type 1 diabetes<\/span><\/h3>\n\n\n\nChemically induced pluripotent stem cells \u2192 islet organoids \u00b7 Peking University \/ Deng lab<\/p>\n\n\n\n
In patients<\/p>\n\n\n\n
BenchPreclinPh 1Ph 2\/3FiledPatients<\/p>\n\n\n\n
DeliveryTransplant under abdominal anterior rectus sheath<\/p>\n\n\n\n
ResultInsulin independence, first reported case, Sept 2024<\/p>\n\n\n\n
Regulatory classCell therapy (ATMP)<\/p>\n\n\n\n
Advantage of chemical routeNo viral vector, no transgene, defined compounds<\/p>\n\n\n\n
This is the field’s real clinical achievement and it is genuine. But read what it is: a bespoke factory. The chemistry ran in a dish for weeks under full control, then stopped. Nothing was reprogrammed inside the patient.<\/p>\n\n\n\n
<\/span>Human chemical reprogramming platform<\/span><\/h3>\n\n\n\nMulti-compound cocktails via an intermediate plastic state \u00b7 Guan 2022; Liuyang 2023<\/p>\n\n\n\n
Bench<\/p>\n\n\n\n
BenchPreclinPh 1Ph 2\/3FiledPatients<\/p>\n\n\n\n
Exposure requiredWeeks of continuous compound, staged protocol<\/p>\n\n\n\n
Key barrier identifiedJNK \/ pro-inflammatory signalling \u2014 inhibition indispensable<\/p>\n\n\n\n
Intermediate stateDedifferentiation the authors liken to axolotl limb regeneration<\/p>\n\n\n\n
FeedsThe factory route above<\/p>\n\n\n\n
The finding worth carrying forward is not the cocktail. It is that inflammation is the brake, not the driver<\/strong> \u2014 established cell-autonomously, in a dish, with no immune system present.<\/p>\n\n\n\nRoute B<\/p>\n\n\n\n
<\/span>In situ \u2014 drug applied to tissue<\/span><\/h2>\n\n\n\nApply an agent to the tissue itself, locally, for a defined time, then withdraw. This is the route that could ever be a product rather than a procedure. No small-molecule reprogramming agent has entered a clinical trial anywhere. The programmes below are what actually occupies this lane.<\/p>\n\n\n\n
<\/span>ER-100 \u2014 partial reprogramming in the eye<\/span><\/h3>\n\n\n\nOCT4 \/ SOX2 \/ KLF4 (OSK), gene therapy \u00b7 Life Biosciences \u00b7 NCT07290244<\/p>\n\n\n\n
Phase 1<\/p>\n\n\n\n
BenchPreclinPh 1Ph 2\/3FiledPatients<\/p>\n\n\n\n
IndicationOpen-angle glaucoma; NAION<\/p>\n\n\n\n
First patient dosed9 June 2026<\/p>\n\n\n\n
EndpointsSafety and tolerability; visual function secondary<\/p>\n\n\n\n
Regulatory classGene therapy \u2014 not<\/em> a small molecule<\/p>\n\n\n\nThe first-in-human partial reprogramming trial exists, and it is transcription factors delivered by vector \u2014 the heavy, expensive, irreversible modality. It is the benchmark to be measured against, not a template to copy.<\/p>\n\n\n\n
<\/span>PY-60 topical gel \u2014 pharmacological YAP activation<\/span><\/h3>\n\n\n\nAnnexin A2 binder, CAS 2765218-56-0 \u00b7 Scripps \/ Calibr \u00b7 Grzelak 2023<\/p>\n\n\n\n
Preclinical<\/p>\n\n\n\n
BenchPreclinPh 1Ph 2\/3FiledPatients<\/p>\n\n\n\n
RouteTopical gel, 0.15% w\/w, every other day<\/p>\n\n\n\n
ModelsYucat\u00e1n mini pig wounds; human skin equivalents; ex vivo human skin<\/p>\n\n\n\n
Beat the approved comparatorYes \u2014 Regranex (becaplermin) failed to move partial-thickness wounds<\/p>\n\n\n\n
ReversibleFully, within 20 days of withdrawal<\/p>\n\n\n\n
The closest thing in this map to your own product space, and the subject of the section below. Note the stage honestly: preclinical. No human trial.<\/p>\n\n\n\n
<\/span>Two-compound rejuvenation cocktail<\/span><\/h3>\n\n\n\nTranylcypromine + RepSox \u00b7 Schoenfeldt 2025 \u00b7 derived from the 7-compound reprogramming set<\/p>\n\n\n\n
In vitro<\/p>\n\n\n\n
BenchPreclinPh 1Ph 2\/3FiledPatients<\/p>\n\n\n\n
CellsAged human dermal fibroblasts (donors 56, 70, 83) and keratinocytes<\/p>\n\n\n\n
Exposure6 days, continuous<\/p>\n\n\n\n
Readouts\u03b3H2AX down, senescence markers down, H3K9me3 \/ H3K27me3 restored<\/p>\n\n\n\n
OrganismC. elegans<\/em> median lifespan 19 \u2192 27 d (+42%)<\/p>\n\n\n\nTwo drugs, six days, and the exact cell types that make up skin. This is the shape of a topical formulation \u2014 but it has never been applied to a wound, to an animal, or to intact skin. The gap between this and a product is entirely unaddressed.<\/p>\n\n\n\n
<\/span>Lorecivivint \u2014 Wnt modulation for cartilage<\/span><\/h3>\n\n\n\nIntra-articular CLK\/DYRK1A inhibitor \u00b7 Biosplice<\/p>\n\n\n\n
NDA filed<\/p>\n\n\n\n
BenchPreclinPh 1Ph 2\/3FiledPatients<\/p>\n\n\n\n
IndicationModerate-to-severe knee osteoarthritis<\/p>\n\n\n\n
NDA submitted6 January 2026<\/p>\n\n\n\n
NotableJoint-structure preservation in Phase 3 \u2014 rare in OA<\/p>\n\n\n\n
Regulatory classSmall molecule, local injection<\/p>\n\n\n\n
Proof that a locally delivered pathway-modulating small molecule with a structural claim can reach an NDA. It is the precedent, not the mechanism.<\/p>\n\n\n\n
<\/span>FX-322 \u2014 the failure to study<\/span><\/h3>\n\n\n\nCHIR99021 + valproic acid, intratympanic \u00b7 Frequency Therapeutics<\/p>\n\n\n\n
Discontinued<\/p>\n\n\n\n
BenchPreclinPh 1Ph 2\/3FiledPatients<\/p>\n\n\n\n
IntentExpand Lgr5+ cochlear progenitors, regrow hair cells<\/p>\n\n\n\n
CompoundsTwo of the seven chemical-reprogramming compounds, exactly<\/p>\n\n\n\n
OutcomePhase 2 missed twice; programme killed, February 2023<\/p>\n\n\n\n
ConsequenceCompany abandoned hearing, cut 55% of staff<\/p>\n\n\n\n
Correct tissue, plausible mechanism, clean preclinical story, right compounds \u2014 and no patient benefit. Any translation claim in this field has to survive being held next to FX-322. It is the single most useful data point on this page.<\/p>\n\n\n\n
Expansion<\/p>\n\n\n\n
<\/span>PY-60: the topical case, read properly<\/span><\/h2>\n\n\n\nCorrection to my earlier note<\/p>\n\n\n\n
I cited \u201cRegeneration and rejuvenation of skin by a topical YAP activator\u201d (PNAS 2023) as the primary paper. It is not.<\/strong> That is a Commentary by James F. Martin \u2014 PNAS 120(32):e2309991120 \u2014 with no abstract and one figure. The primary research article is Grzelak et al., PNAS 2023;120(28):e2305085120<\/strong>, from Scripps Research \/ Calibr.<\/p>\n\n\n\nI also wrote that it \u201cshifts cutaneous wound repair toward regeneration rather than scar.\u201d That claim is not supported by the paper.<\/strong> Scar was not characterised: no Engrailed-1 lineage work, no myofibroblast markers, no quantified collagen organisation. Masson’s trichrome was performed on pig wounds for collagen deposition, but no scar outcome is reported. What the paper actually demonstrates is accelerated re-epithelialisation and regranulation. The word \u201cregenerative\u201d is theirs; the anti-scar reading was mine, and it was wrong.<\/p>\n\n\n\n<\/span>What the compound is<\/span><\/h3>\n\n\n\nPY-60 is not a LATS or Hippo-kinase inhibitor<\/strong>, which is how most secondary sources describe this class. Its molecular target is Annexin A2<\/strong> (Kd<\/sub> \u2248 1.4 \u00b5M; cellular EC50<\/sub> for YAP activation \u2248 1.6 \u00b5M). ANXA2 normally shepherds YAP to the plasma membrane, where YAP receives inhibitory phosphorylation. PY-60 binds ANXA2 and blocks that trafficking, so YAP escapes membrane-localised inactivation and accumulates in the nucleus. It acts upstream of, and parallel to, the kinase cassette \u2014 on YAP’s location<\/em>, not its phosphorylation state directly.<\/p>\n\n\n\n<\/span>What was actually done<\/span><\/h3>\n\n\n\n| Model<\/th> | Regimen<\/th> | Result<\/th><\/tr><\/thead> |
|---|
| Mouse, intact skin (PD only \u2014 no wound model)<\/td> | 10 mg\/mL gel, once daily \u00d7 10 d<\/td> | ~4\u00d7 epidermal thickness. Solvent formulations (acetone, DMSO) gave only ~2\u00d7.<\/td><\/tr> |
| Yucat\u00e1n mini pig, intact skin<\/td> | 0.15 wt% once daily \u00d7 10 d<\/td> | Epidermal thickness ~40 \u00b5m \u2192 ~60 \u00b5m (\u2248 +50%)<\/td><\/tr> |
| Yucat\u00e1n mini pig wounds \u2014 3 \u00d7 3 cm, partial and full thickness, 4 animals<\/td> | 0.15 wt% every other day over 8 d<\/td> | Markedly accelerated closure of both wound types. Final epidermal thickness ~2\u00d7 that of Regranex.<\/td><\/tr> |
| Regranex comparator (becaplermin, 0.01% rhPDGF)<\/td> | Same pig wounds<\/td> | No effect in partial-thickness wounds.<\/strong> Modest acceleration in full-thickness only.<\/td><\/tr>| Human skin equivalents (EpiDermFT), 3 mm full-thickness<\/td> | 0.2\u20130.5 \u00b5M, 72 h<\/td> | Accelerated closure; outperformed 1% FBS and 10 ng\/mL rhPDGF<\/td><\/tr> | | Ex vivo human skin (abdominoplasty)<\/td> | 7 d<\/td> | >2\u00d7 epidermal thickness; increased rete peg density<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<\/span>The two facts that matter commercially<\/span><\/h3>\n\n\n\nThe vehicle was worth as much as the molecule.<\/strong> Same compound, same dose, same duration: the gel produced roughly twice the effect of solvent formulations. The gel is propylene glycol 26% \/ Labrasol ALF 17.5% \/ PEG 400 46.5% \/ Povidone K-90 8.5%, with PY-60 at 0.15% or 1.5% w\/w. A pharmacology lab published that formulation in a methods section and moved on. It is not their competence and they did not optimise it.<\/p>\n\n\n\nThe approved comparator failed.<\/strong> Becaplermin is the reference growth-factor product for chronic wounds and it did nothing to partial-thickness pig wounds in this study. The bar in this indication is low, and it is low because delivery to a wound bed is unsolved, not because the biology is.<\/p>\n\n\n\n<\/span>Reversibility \u2014 the safety argument and the therapeutic ceiling<\/span><\/h3>\n\n\n\nMice treated for 10 days and then left alone for 20 were statistically indistinguishable from vehicle controls on epidermal thickness, Ki-67 positivity and dermal nuclei. Systemic exposure is negligible (t\u00bd<\/sub> = 0.46 h, rapid hepatic clearance, no YAP activation in internal organs). No fibroblast cytotoxicity to 100 \u00b5M. No phototoxicity under solar irradiation.<\/p>\n\n\n\nThe authors offer reversibility as their answer to the obvious objection \u2014 YAP is an overgrowth node. Note where the cancer framing actually comes from: Martin’s commentary<\/em> raises squamous carcinoma, citing Debaugnies 2018, that sustained active YAP causes skin cancer in mice. The primary paper contains no SCC statement and no carcinogenicity, long-term, or dysplasia-histopathology study was performed.<\/strong> Attribute that risk discussion correctly if you write about it.<\/p>\n\n\n\nAnd read reversibility the other way too: it confirms the governing constraint at the top of this page. PY-60 does not start a programme that runs. It holds a proliferative state open while the drug is present, and the state collapses when it is withdrawn. That is exactly the safety feature and exactly the therapeutic limit.<\/p>\n\n\n\n Position<\/p>\n\n\n\n <\/span>Where a topical wound programme enters<\/span><\/h2>\n\n\n\nThe translatable unit is not \u201creprogramming.\u201d It is a short, local, withdrawable chemical modulation of a repair programme the tissue already has. Four propositions, ordered by how cheaply each can be killed.<\/p>\n\n\n\n 01<\/p>\n\n\n\n <\/span>The bottleneck is delivery, and delivery is a device problem<\/span><\/h3>\n\n\n\nA pharmacology lab’s throwaway gel doubled its own compound’s effect. Exposure control \u2014 concentration held at the wound bed, for a defined window, then removed \u2014 is formulation and dressing work. That is your competence and a stem-cell lab’s blind spot. It is also the cheapest place in this whole map to generate a defensible position.<\/p>\n\n\n\n 02<\/p>\n\n\n\n <\/span>A wound bed is the only tissue where the window is physically controllable<\/span><\/h3>\n\n\n\nEvery partial-reprogramming protocol that works imposes closure from outside \u2014 a timer, a cycle, a withdrawal. In the eye or the pancreas that timer has to be engineered into a vector. On a wound you apply, hold and remove. The requirement your own framework identifies \u2014 open the window, then close it \u2014 is solved by a dressing rather than by biology.<\/p>\n\n\n\n 03<\/p>\n\n\n\n <\/span>Test the brake, not the accelerator<\/span><\/h3>\n\n\n\nHuman chemical reprogramming found JNK \/ pro-inflammatory signalling to be the barrier whose removal permits plasticity \u2014 cell-autonomously, with no immune system in the dish. Your own wound reading converges: germ-free skin closes faster and scarless, L. reuteri<\/em> accelerates closure with fewer neutrophils, and the shared variable across both is inflammatory load rather than microbial presence.<\/p>\n\n\n\nLowering local inflammatory tone and letting the endogenous programme run is a cheaper hypothesis to test and a far lighter regulatory object than pushing cells uphill with a proliferative agonist. It also avoids inheriting YAP’s oncogene problem.<\/p>\n\n\n\n 04<\/p>\n\n\n\n <\/span>Whatever you choose has to survive FX-322<\/span><\/h3>\n\n\n\nCorrect target tissue, correct compounds, plausible mechanism, clean preclinical data, two failed Phase 2 trials and a dead company. Before committing, state in one sentence what makes your candidate different from FX-322 \u2014 and if the answer is only \u201cdifferent tissue,\u201d it is not an answer.<\/p>\n\n\n\n Audit<\/p>\n\n\n\n <\/span>Established, inferred, and unverified<\/span><\/h2>\n\n\n\nSplit explicitly, so nothing on this page enters a manuscript at the wrong confidence.<\/p>\n\n\n\n Established<\/p>\n\n\n\n \n- PY-60 targets Annexin A2; compound identity, Kd<\/sub>, EC50<\/sub>, gel composition and dosing all verified against the article’s own text.<\/li>\n\n\n\n
- Pig epidermal thickening ~40 \u2192 ~60 \u00b5m; Regranex null in partial-thickness wounds; >2\u00d7 epidermal thickness and increased rete pegs in human explants.<\/li>\n\n\n\n
- Full reversal of PY-60 effects 20 days after withdrawal; PK and phototoxicity findings.<\/li>\n\n\n\n
- CiPSC-islet transplantation with insulin independence; ER-100 first dose 9 June 2026; lorecivivint NDA 6 January 2026; FX-322 discontinuation.<\/li>\n\n\n\n
- JNK inhibition as the indispensable barrier-removal step in human chemical reprogramming.<\/li>\n<\/ul>\n\n\n\n
Inferred<\/p>\n\n\n\n | |